Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Plans To Trial Antimicrobial Voucher Scheme For 15 Years

Executive Summary

Proposals for an EU voucher that would encourage the development of “game-changing” antimicrobials are accompanied by plans for procurement mechanisms to guarantee revenues for companies regardless of sales volumes. But one law firm said the conditions attached to the voucher were so strict that the scheme appeared “unworkable.”

You may also be interested in...



EU Ministers Endorse ‘Multi-Country Pull Incentive’ For New Antimicrobial R&D

Although it is not legally binding, a recommendation endorsed this week by the Council of the EU will give countries more tools to tackle the thorny problem of resistance to antimicrobial drugs, according to the Swedish presidency of the council.

European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials

The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.

UK Offers Fresh Funding For New Drugs & Vaccines Against AMR

New funding from the UK’s antimicrobial resistance innovation fund is to be welcomed, but the UK pharmaceutical industry body, the ABPI, has cautioned that “multiple global solutions” bringing together governments, health care systems and the industry are needed if research efforts are to result in effective new antibiotics.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel